반응식
[CH:1]1([N:4]([CH:18]2[CH2:23][CH2:22][NH:21][CH2:20][CH2:19]2)[C:5](=[O:17])[C:6]2[CH:11]=[CH:10][C:9]([C:12]3[O:16][CH:15]=[N:14][CH:13]=3)=[CH:8][CH:7]=2)[CH2:3][CH2:2]1.[Br:24][C:25]1[CH:26]=[CH:27][C:28](F)=[N:29][CH:30]=1>>[Br:24][C:25]1[CH:26]=[CH:27][C:28]([N:21]2[CH2:22][CH2:23][CH:18]([N:4]([CH:1]3[CH2:3][CH2:2]3)[C:5](=[O:17])[C:6]3[CH:7]=[CH:8][C:9]([C:12]4[O:16][CH:15]=[N:14][CH:13]=4)=[CH:10][CH:11]=3)[CH2:19][CH2:20]2)=[N:29][CH:30]=1참가 물질
3
실험 절차
The title compound is prepared from N-cyclopropyl-4-oxazol-5-yl-N-piperidin-4-yl-benzamide and 5-bromo-2-fluoro-pyridine following a procedure analogous to that described in Example 19. LC (method 10): tR=1.92 min; Mass spectrum (ESI+): m/z=467/469 (Br) [m+H]+.
출처 및 근거
- ORD 기록
- ord-d617ddf9374b4e66a3a1e89941460e9f
- 출처 데이터셋
- uspto-grants-2014_09
- 특허 번호
- US08822471B2
연결된 노트
불러오는 중…